Invention Grant
- Patent Title: Human bispecific EGFRvIII and CD3 antibody engaging molecules
-
Application No.: US14903659Application Date: 2014-07-09
-
Publication No.: US10053514B2Publication Date: 2018-08-21
- Inventor: Darell D. Bigner , John Sampson , Chien-Tsun Kuan , Mingqing Cai , Bryan D. Choi , Patrick C. Gedeon , Ira H. Pastan
- Applicant: DUKE UNIVERSITY , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
- Applicant Address: US NC Durham US DC Washington
- Assignee: Duke University,The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
- Current Assignee: Duke University,The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
- Current Assignee Address: US NC Durham US DC Washington
- Agency: Banner & Witcoff, Ltd.
- International Application: PCT/US2014/046003 WO 20140709
- International Announcement: WO2015/006482 WO 20150115
- Main IPC: C07K16/46
- IPC: C07K16/46 ; A61K39/395 ; C12N15/09 ; C12N15/11 ; C07K16/32 ; C07K16/28 ; C07K16/40 ; A61K39/00
Abstract:
We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.
Public/Granted literature
- US20160168263A1 Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules Public/Granted day:2016-06-16
Information query
